These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

60 related items for PubMed ID: 9632956

  • 1. Does obesity influence ciprofibrate activity?
    Silva JM, Serra e Silva P.
    Rev Port Cardiol; 1998 Apr; 17(4):329-34. PubMed ID: 9632956
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
    Am J Ther; 2007 Apr; 14(2):213-20. PubMed ID: 17414592
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of metabolic syndrome among Filipino adults aged 20 years and over.
    Tanchoco CC, Cruz AJ, Duante CA, Litonjua AD.
    Asia Pac J Clin Nutr; 2003 Apr; 12(3):271-6. PubMed ID: 14505989
    [Abstract] [Full Text] [Related]

  • 5. [Body fat distribution: its characteristics and relationship to cardiovascular risk factors in obese Chinese].
    Ran XW, Li XS, Tong NW, Li QF, Tang BD, Li XJ.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Sep; 35(5):699-703. PubMed ID: 15460424
    [Abstract] [Full Text] [Related]

  • 6. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
    Kovács I, Tarján J, Császár A.
    Orv Hetil; 2001 Apr 15; 142(15):775-9. PubMed ID: 11367862
    [Abstract] [Full Text] [Related]

  • 7. [Ciprofibrate in the treatment of combined hyperlipoproteinemia. Results in more than 600 patients from 23 centers in the Czech Republic].
    Ceska R, Kvasnicka T, Haas T, Soska V, Vaverková H.
    Vnitr Lek; 2000 Mar 15; 46(3):157-60. PubMed ID: 11048518
    [Abstract] [Full Text] [Related]

  • 8. Prothrombotic and lipoprotein variables in patients attending a cardiovascular risk management clinic: response to ciprofibrate or lifestyle advice.
    Mikhailidis DP, Ganotakis ES, Spyropoulos KA, Jagroop IA, Byrne DJ, Winder AF.
    Int Angiol; 1998 Dec 15; 17(4):225-33. PubMed ID: 10204653
    [Abstract] [Full Text] [Related]

  • 9. [Postprandial changes of blood lipid after ordinary Chinese diet and the influencing factors thereof].
    Fu ZF, Liu ML.
    Zhonghua Yi Xue Za Zhi; 2009 Feb 03; 89(4):260-2. PubMed ID: 19552844
    [Abstract] [Full Text] [Related]

  • 10. Temporal changes in anthropometric parameters and lipid profile according to body mass index among an adult Iranian urban population.
    Bozorgmanesh MR, Hadaegh F, Padyab M, Mehrabi Y, Azizi F.
    Ann Nutr Metab; 2008 Feb 03; 53(1):13-22. PubMed ID: 18772585
    [Abstract] [Full Text] [Related]

  • 11. [Plasma levels of adiponectin and tumor necrosis factor-alpha in children with obesity].
    Yan WJ, Wu J, Mo J, Huang CW, Peng LW, Xu L.
    Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan 03; 11(1):47-50. PubMed ID: 19149923
    [Abstract] [Full Text] [Related]

  • 12. [Safety of ciprofibrate. Open study in a Portuguese population].
    Branco MC, de Moura JP, Pereira M, Jesus LC, Ferraz A, Silva JM, Ferreira MR, Serra e Silva P.
    Rev Port Cardiol; 1995 May 03; 14(5):395-9, 360. PubMed ID: 7654400
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS, Milionis HJ, Filippatos TD, Nakou ES, Bairaktari ET, Tselepis AD, Elisaf MS.
    Clin Ther; 2007 Jul 03; 29(7):1403-14. PubMed ID: 17825691
    [Abstract] [Full Text] [Related]

  • 16. Prescreening tools for diabetes and obesity-associated dyslipidaemia: comparing BMI, waist and waist hip ratio. The D.E.S.I.R. Study.
    Balkau B, Sapinho D, Petrella A, Mhamdi L, Cailleau M, Arondel D, Charles MA, D.E.S.I.R. Study Group.
    Eur J Clin Nutr; 2006 Mar 03; 60(3):295-304. PubMed ID: 16278693
    [Abstract] [Full Text] [Related]

  • 17. Microcirculatory damage of common carotid artery wall in obese and non obese subjects.
    Ciccone M, Maiorano A, De Pergola G, Minenna A, Giorgino R, Rizzon P.
    Clin Hemorheol Microcirc; 1999 Mar 03; 21(3-4):365-74. PubMed ID: 10711772
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Insulin sensitivity indices of glucose and free fatty acid metabolism in obese children and adolescents in relation to serum lipids.
    Reinehr T, Kiess W, Andler W.
    Metabolism; 2005 Mar 03; 54(3):397-402. PubMed ID: 15736120
    [Abstract] [Full Text] [Related]

  • 20. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.
    Clin Ther; 2007 Aug 03; 29(8):1671-81. PubMed ID: 17919548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.